How do you get sales to support a win/loss research program?
Sales supports a win/loss research program through executive sponsorship of the program’s scope, not through approving which individual deals get reviewed. Pulling the deal list directly from the CRM under executive sponsorship, rather than asking sales to select or exclude specific deals, avoids the selection bias that individual approval introduces and still gives sales leadership a stake in the program.
That distinction, sponsorship versus approval, is the difference between a program that gets a representative sample and one that doesn’t.
Why Deal-by-Deal Approval Backfires
Involving sales in deal selection feels collaborative, but it hands curation of the deal pool to the people whose read on each loss is, by definition, one-sided. A rep’s account of why a deal was lost is built from what they observed, what the buyer told them directly, and the story they’ve constructed to make sense of the outcome. That account isn’t necessarily wrong, but when it is, the deals a rep flags as not worth reviewing are frequently the ones where the buyer’s actual reason for leaving would be most revealing.
Reps also hesitate to include deals they’re uncertain about, not out of an intent to obscure anything, but because deal-by-deal approval can feel indistinguishable from a rep review. Win/loss done correctly has nothing to do with individual performance assessment. It’s pattern recognition across a body of deals. If that distinction isn’t established clearly before the program starts, hesitation is a reasonable response, and the deal list it produces will reflect it.
What Executive Sponsorship Looks Like in Practice
The alternative is setting the program’s scope, defining the research timeframe, and pulling the deal list directly from the CRM under an executive sponsor’s authority, rather than routing each deal through sales for individual sign-off. Sales leadership supporting the program at the scope level is a different thing from sales approving which conversations happen deal by deal, and that difference is what keeps the sample representative.
Communicating the Distinction to Sales
Sales teams are more likely to support a program once it’s clear that win/loss research isn’t evaluating individual reps or specific deals they handled. Framing the program explicitly as pattern recognition across an aggregated deal set, with findings distributed as GTM-level insight rather than deal-specific critique, removes the incentive for any individual rep to feel exposed by the process.
Where Sales Should Still Be Involved
Excluding sales from deal-level approval doesn’t mean excluding sales leadership from the program entirely. Sales leadership can be informed of the research window and deal set in advance, consulted on which segments or deal types the program should prioritize at a strategic level, and included among the stakeholders who receive findings in the readout. The line to hold is between strategic input at the program level and case-by-case approval at the deal level, since the second is where selection bias enters.
What Happens When This Distinction Isn’t Made Clear
Programs that blur the line between sponsorship and approval often end up with sales quietly filtering which deals get flagged for outreach, even without an explicit veto process in place. Establishing the CRM-sourced, executive-sponsored deal list as the standard before the first outreach campaign goes out avoids this ambiguity from taking hold once the program is underway.